Anaptysbio (ANAB) Free Cash Flow Growth (5y) (2021 - 2026)
Anaptysbio (ANAB) Free Cash Flow Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Anaptysbio | 1.54 Bn | 1.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.97% |
| Dec 31, 2025 | 21.31% |
| Sep 30, 2025 | -9.79% |
| Jun 30, 2025 | -15.40% |
| Mar 31, 2025 | 6.76% |
| Dec 31, 2024 | -33.19% |
| Sep 30, 2024 | 15.13% |
| Jun 30, 2024 | -6.82% |
| Mar 31, 2024 | -18.02% |
| Dec 31, 2023 | -22.61% |
| Sep 30, 2023 | -19.27% |
| Jun 30, 2023 | -22.17% |
| Mar 31, 2023 | -14.66% |
| Dec 31, 2022 | -16.73% |
| Sep 30, 2022 | -36.53% |
| Jun 30, 2022 | -54.79% |
| Mar 31, 2022 | -20.83% |
| Dec 31, 2021 | -35.37% |
| Sep 30, 2021 | -13.69% |
| Jun 30, 2021 | 39.93% |